Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Jan_Mikkelsen
|
| gptkbp:country |
gptkb:Denmark
|
| gptkbp:focus |
oncology
endocrinology rare diseases |
| gptkbp:founded |
2007
|
| gptkbp:founder |
gptkb:Jan_Mikkelsen
|
| gptkbp:hasCompany |
yes
|
| gptkbp:headquarters_location |
gptkb:Copenhagen,_Denmark
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ascendis Pharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US04351P1012
|
| gptkbp:listedOn |
gptkb:NASDAQ_Global_Select_Market
|
| gptkbp:numberOfEmployees |
over 700
|
| gptkbp:pipeline |
gptkb:TransCon_hGH
gptkb:TransCon_CNP gptkb:TransCon_PTH |
| gptkbp:platform |
TransCon technology
|
| gptkbp:product |
gptkb:Skytrofa
|
| gptkbp:Skytrofa_indication |
growth hormone deficiency
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ASND
|
| gptkbp:website |
https://www.ascendispharma.com/
|
| gptkbp:bfsParent |
gptkb:Sofinnova_Partners
|
| gptkbp:bfsLayer |
7
|